Patents by Inventor XBiotech, Inc.

XBiotech, Inc. has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • TREATMENT OF CACHEXIA BY TARGETING INTERLEUKIN-1 BETA
    Publication number: 20130195877
    Abstract: Administration of a mAb that specifically binds IL-1? is used for treating cachexia in human subjects.
    Type: Application
    Filed: January 28, 2013
    Publication date: August 1, 2013
    Applicant: XBiotech, Inc.
    Inventor: XBiotech, Inc.
  • Interleukin-1 Alpha Antibodies and Methods of Use
    Publication number: 20130177982
    Abstract: Fully human monoclonal Abs includes (i) an antigen-binding variable region that exhibits very high binding affinity for IL-1? and (ii) a constant region that is effective at both activating the complement system though C1q binding and binding to several different Fc receptors.
    Type: Application
    Filed: February 14, 2013
    Publication date: July 11, 2013
    Applicant: XBIOTECH, INC.
    Inventor: XBiotech, Inc.
  • Interleukin-1 Alpha Antibodies and Methods of Use
    Publication number: 20130171728
    Abstract: Fully human monoclonal Abs includes (i) an antigen-binding variable region that exhibits very high binding affinity for IL-1? and (ii) a constant region that is effective at both activating the complement system though C1q binding and binding to several different Fc receptors.
    Type: Application
    Filed: February 8, 2013
    Publication date: July 4, 2013
    Applicant: XBIOTECH, INC.
    Inventor: XBiotech, Inc.
  • Cachexia Treatment
    Publication number: 20130078258
    Abstract: Administration of an antibody that specifically binds IL-1? is useful for treating cachexia and increasing the lifespan of a subject suffering from cachexia.
    Type: Application
    Filed: September 21, 2012
    Publication date: March 28, 2013
    Applicant: XBIOTECH, INC.
    Inventor: XBiotech, Inc.
  • Treatment of Inflammatory Skin Disease and Psychiatric Conditions
    Publication number: 20130039921
    Abstract: The number of acne lesions in a human subject is reduced by administering to the subject a pharmaceutical composition that includes a pharmaceutically acceptable carrier and a therapeutically effective amount of an agent that selectively binds IL-1?. Anxiety and other psychiatric conditions are also improved with this treatment.
    Type: Application
    Filed: October 4, 2012
    Publication date: February 14, 2013
    Applicant: XBIOTECH, INC.
    Inventor: XBiotech, Inc.